CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy
Clearside Biomedical’s CLSD stock is in freefall today after the eye‑disease biotech announced a voluntary Chapter 11 bankruptcy filing and plans to pursue a court‑supervised sale of its business and assets.